MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-6,400 -5,600
Stock-based compensation
685 1,734
Issuance of share capital for payments in kind
0 27
Depreciation and amortization
-0
Accretion of debt issuance costs on notes payable and notes payable, related party
93 -
Gain on settlement of current liabilities
774 1,244
Loss on debt extinguishment
-967 -
Change in fair value of warrant liabilities
253 80
Impairment loss on other intangible assets
5,180 -
Loss on derivative liability
-100 -
Deferred tax benefit
-1,088 -
Unrealized foreign currency exchange (gains) losses
56 394
Prepaid expenses and other current assets
-129 -263
Accounts payable and accrued expenses
-704 -112
Net cash used in operating activities
-2,121 -5,406
Proceeds from issuance of shares, net of issuance costs
0 5,879
Proceeds from issuance of notes payable
2,099 -
Proceeds from employee vesting of restricted shares
0 33
Proceeds from pre-funded warrants
0 330
Repayments of notes payable
-33 -455
Proceeds from issuance of convertible notes
-0
Payments on short-term financing arrangement
169 273
Net cash provided by financing activities
1,897 5,514
Effect of exchange rates on cash
-3 4
Net change in cash
-227 112
Cash and cash equivalents at beginning of period
2,659 -
Cash and cash equivalents at end of period
2,544 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Akari Therapeutics Plc (AKTX)

Akari Therapeutics Plc (AKTX)